On September 21, 2017– BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, reported that Co-Chief Executive Officer Adi Mohanty will participate in a panel discussion at Cell & Gene Therapy CEO on Monday, September 25, 2017 in Boston (Press release, BioTime, SEP 21, 2017, View Source [SID1234520580]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The panel, titled "Financing Innovation: Attracting Investment" is at 2:00pm ET/11:00am PT. The discussion will be moderated by Rich Daly, Chairman and CEO of Neuralstem. Panelists include Mark Barrett, Entrepreneur-in-Residence, Frazier Healthcare Partners, David Grainger, Ph.D., CEO of Methuselah Health and Partner at Medicxi, and Nora Yang, Director, Portfolio Management & Strategic Operations at the National Center for Advancing Translational Sciences, National Institutes of Health.
Cell & Gene Therapy CEO is an off-the-record networking forum that brings together CEOs and decision makers in cell therapy, gene therapy, and regenerative medicine. Intimate discussion panels, keynotes and fireside chats feature thought leaders debating business model efficiencies, financing, regulatory issues, market access and reimbursement, novel partnerships, manufacturing, and delivery challenges. Healthcare investors and leading researchers also participate.